Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 19, 2019
Daily News
November 19, 2019
- Regenerative Medicine Industry Calls for Appropriate Reward for Innovation: Public-Private Confab
November 19, 2019
- Mitsubishi Chemical to Fully Own Mitsubishi Tanabe to Solidify Healthcare Platform
November 19, 2019
- Fujifilm Kicks Off US PI Study for Topotecan Liposome Drug
November 19, 2019
- RIKEN Develops Supercomputer for Molecular Dynamics Simulation, Will Be Made Available to Drug Makers for Drug Discovery Use
November 19, 2019
- Takeda Eyes 12 NME Approvals over Next 5 Years
November 19, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…